<i>Arisaema heterophyllum Blume</i> Monomer Stigmasterol Targets PPAR<i>γ</i> and Inhibits the Viability and Tumorigenicity of Lung Adenocarcinoma Cells NCI-H1975

<div>Network pharmacology and molecular docking analyzes the regulatory relationship between AhBl-stigmasterol-lung adenocarcinoma-PPAR<i>γ</i>. (a) Venn diagram of AhBl drug targets and lung adenocarcinoma-related targets. (b) Network pharmacological interaction diagram. (c) Molecular docking results. Stigmasterol is the main active component of AhBl. TNX indicates AhBl; TNX1 is 8,11,14-docosatrienoic acid, methyl ester; TNX2 is [(2R)-2-[[[(2R)-2-(benzoylamino)-3-phenylpropanoyl]amino]methyl]-3-phenylpropyl] acetate; TNX4 is sitosterol.</div>

Evidence-Based Complementary and Alternative Medicine

fig1

Figure 1

Figure 1: <i>Arisaema heterophyllum Blume</i> Monomer Stigmasterol Targets PPAR<i>γ</i> and Inhibits the Viability and Tumorigenicity of Lung Adenocarcinoma Cells NCI-H1975 

Figure 1 | Arisaema heterophyllum Blume Monomer Stigmasterol Targets PPARγ and Inhibits the Viability and Tumorigenicity of Lung Adenocarcinoma Cells NCI-H1975 